Roxadustat vs Meldonium
Head-to-head comparison of Roxadustat (Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor) and Meldonium (3-(2,2,2-Trimethylhydrazinium)propionate) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Roxadustat | Meldonium |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor | 3-(2,2,2-Trimethylhydrazinium)propionate |
| Molecular Weight | 352.35 Da | 146.19 Da |
| Half-Life | ~12-16 h | ~3-6 h |
| Amino Acids | N/A | N/A |
| Typical Dose | 70-100 mg orally three times weekly | 500-1000 mg/day in divided oral doses |
| Route | Oral | Oral/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 180 | 70 |
| Research Status | Clinical | Clinical |
Roxadustat Benefits
- ✓induces endogenous EPO
- ✓improves iron handling
- ✓raises hemoglobin
- ✓may improve exercise tolerance
Meldonium Benefits
- ✓improves exercise tolerance
- ✓may reduce ischemic fatigue
- ✓supports metabolic efficiency
- ✓may aid recovery
Roxadustat Dosing
70-100 mg orally 3x weekly|Titrate by hemoglobin response|Monitor iron indices regularly
Meldonium Dosing
500 mg orally daily|500 mg orally twice daily|500-1000 mg/day in divided doses
Roxadustat Side Effects
- ⚠nausea
- ⚠hypertension
- ⚠thrombotic events
Meldonium Side Effects
- ⚠GI upset
- ⚠headache
- ⚠palpitations
Research Overview
Roxadustat
Large clinical studies support roxadustat for anemia, especially in chronic kidney disease populations. Direct VO2 max enhancement data in healthy athletes are limited, so its performance effects remain mostly inferential.
Meldonium
Clinical literature focuses on cardiometabolic support and exercise tolerance rather than direct anabolic effects. Any endurance benefit is thought to come from altered substrate handling and improved tolerance to stress.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.